Abaloparatide
From Wikipedia, the free encyclopedia
| Systematic (IUPAC) name | |
|---|---|
|
L-alanyl-L-valyl-L-seryl-L-α-glutamyl-L-histidyl-L-glutaminyl-L-leucyl-L-leucyl-L-histidyl-L-α-aspartyl-L-lysylglycyl-L-lysyl-L-seryl-L-isoleucyl-L-glutaminyl-L-α-aspartyl-L-leucyl-L-arginyl-L-arginyl-L-arginyl-L-α-glutamyl-L-leucyl-L-leucyl-L-α-glutamyl-L-lysyl-L-leucyl-L-leucyl-2-methylalanyl-L-lysyl-L-leucyl-L-histidyl-L-threonyl-L-alaninamide
|
|
| Clinical data | |
| Routes of administration |
Subcutaneous injection |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | 247062-33-5 |
| ATC code | none |
| PubChem | CID 76943386 |
| ChemSpider | 34443170 |
| UNII | AVK0I6HY2U |
| Synonyms | BA058, BIM-44058 |
| Chemical data | |
| Formula | C174H299N56O49 |
| Molar mass | 3,959.65 g·mol−1 |
| 3D model (Jmol) | Interactive image |
|
|
|
|
Abaloparatide is a parathyroid hormone-related protein (PTHrP) analog drug in development for treating osteoporosis.[1] Like the related drug teriparatide, and unlike bisphosphonates, it is an anabolic (i.e., bone growing) agent.[2]
A subcutaneous injection formulation of the drug has completed a Phase III trial for osteoporosis.[3] This single study found a decrease in fractures.[4] A transdermal patch is also in development.[2]
References[edit]
- ^ http://www.genengnews.com/gen-news-highlights/radius-raises-26-75m-for-phase-iii-osteoporosis-trial/81245990/
- ^ a b H. Spreitzer (18 January 2016). "Neue Wirkstoffe – Abaloparatid". Österreichische Apothekerzeitung (in German) (2/2016): 12.
- ^ Clinical trial number NCT01343004 for "Phase III Study to Evaluate the Safety and Efficacy of BA058 for Prevention of Fracture in Postmenopausal Women" at ClinicalTrials.gov
- ^ Miller, PD; Hattersley, G; Riis, BJ; Williams, GC; Lau, E; Russo, LA; Alexandersen, P; Zerbini, CA; Hu, MY; Harris, AG; Fitzpatrick, LA; Cosman, F; Christiansen, C; ACTIVE Study, Investigators. (16 August 2016). "Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.". JAMA. 316 (7): 722–33. PMID 27533157.
 |
This hormonal preparation article is a stub. You can help Wikipedia by expanding it. |
